Denali Therapeutics (NASDAQ: DNLI) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Denali Therapeutics to related companies based on the strength of its profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and earnings.
This is a summary of current ratings and price targets for Denali Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Denali Therapeutics Competitors||1150||3475||11993||243||2.67|
Denali Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 21.46%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.25%. Given Denali Therapeutics’ peers higher possible upside, analysts plainly believe Denali Therapeutics has less favorable growth aspects than its peers.
Insider and Institutional Ownership
49.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Denali Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Denali Therapeutics Competitors||-5,387.53%||-161.65%||-35.78%|
Earnings & Valuation
This table compares Denali Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Denali Therapeutics Competitors||$290.27 million||$35.99 million||59.36|
Denali Therapeutics’ peers have higher revenue and earnings than Denali Therapeutics.
Denali Therapeutics Company Profile
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.